GlassScriptPhysician profile
Emily G Singh
NPI 1548370935
$7,424.08
in general payments reported to CMS, 2019-2025
30 companies · $1,484 in 2025
The $1,484 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $913 · 2020: $479 · 2021: $559 · 2022: $1,013 · 2023: $1,540 · 2024: $1,437 · 2025: $1,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,460.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,410.04 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $1,350.73 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,004.09 | 2019-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $386.63 | 2019-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $381.53 | 2019-2025 | Xifaxan |
| Pfizer INC. | $339.11 | 2019-2025 | |
| Ardelyx, INC. | $222.33 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $220.42 | 2022-2025 | |
| Celgene Corporation | $148.62 | 2022-2023 | Zeposia |
| Janssen Scientific Affairs, LLC | $143.20 | 2020 | |
| Braintree Laboratories, INC. | $104.16 | 2019-2023 | Sutab, Suflave |
| Qol Medical, LLC | $100.25 | 2019-2024 | Sucraid |
| Phathom Pharmaceuticals, INC. | $96.55 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $65.52 | 2019-2024 | Dificid, Zerbaxa |
| Allergan, INC. | $57.48 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $52.43 | 2023 | Nucala |
| Janssen Pharmaceuticals, INC | $42.46 | 2021 | |
| Lilly USA, LLC | $40.01 | 2024-2025 | Omvoh, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.10 | 2020-2023 | Cyltezo |
| Celltrion USA INC. | $36.62 | 2025 | Vegzelma |
| Enterra Medical, INC. | $25.79 | 2023 | |
| Ironwood Pharmaceuticals, INC | $23.80 | 2024 | |
| Aimmune Therapeutics, INC. | $23.17 | 2025 | Zenpep |
| Acorda Therapeutics, INC | $21.14 | 2019 | |
| Mallinckrodt Hospital Products INC. | $19.93 | 2025 | Acthar |
| Romark Laboratories, Lc | $16.22 | 2019 | |
| Shionogi INC | $16.20 | 2019 | |
| Intercept Pharmaceuticals, INC. | $13.94 | 2021 | |
| Gilead Sciences, INC. | $13.28 | 2019 | |
| Pentax of America, INC. | $11.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.